Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sanofi Boosts Role In Contract Production
by Rick Mullin
April 1, 2013
| A version of this story appeared in
Volume 91, Issue 13
Sanofi and Transgene will jointly invest $13 million to build an active pharmaceutical ingredients (API) facility at a site in the Lyon-Gerland area of France, operated by Sanofi’s Genzyme subsidiary. Sanofi will supply Transgene with clinical- and commercial-scale batches of API for Transgene’s immunotherapy products, including its MVA therapeutic vaccines, under a new contract manufacturing agreement. The facility will be owned by Sanofi. Separately, Sanofi will manufacture protein-extract-based APIs for DBV Technologies’ Viaskin allergy treatment at its plant in Aramon, France.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter